RIGL
insider transactionsRIGEL PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-6.5K
0 buy · 6.5K sell
Net value · 365d
-$218.4K
$0 in · $218.4K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
2
0 buy · 6.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Dean L Schorno KEY
EVP & Chief Financial Officer
$0
2.2K sh
Own +19%
-
Exercise·M
Dean L Schorno KEY
EVP & Chief Financial Officer
$0
1.2K sh
Own +14%
-
Other·F
Dean L Schorno KEY
EVP & Chief Financial Officer
$27.7K
928 sh · $29.86
Own -1%
-
Exercise·M
Dean L Schorno KEY
EVP & Chief Financial Officer
$27.7K
2.2K sh · $12.70
Own +3%
-
Exercise·M
Dean L Schorno KEY
EVP & Chief Financial Officer
$22.4K
1.2K sh · $18.70
Own +2%
-
Other·F
EVP, Chief Commercial Officer
$26.1K
874 sh · $29.86
Own -1%
-
Other·F
EVP, Chief Medical Officer
$25.4K
850 sh · $29.86
Own -2%
-
Other·F
Raul R Rodriguez KEY
CEO, President
$72.4K
2.4K sh · $29.86
Own -1%
-
Other·F
EVP, GC, CCO & Corp Sec
$26.2K
877 sh · $29.86
Own -2%
-
Sell·S
Director · 10b5-1
$72.9K
2.5K sh · $29.17
Own -17%
-
Grant·A
Director
$0
5.8K sh
Own +46%
-
Grant·A
Director
$0
5.8K sh
Own +45%
-
Grant·A
Director
$0
5.8K sh
Own +46%
-
Grant·A
Director
$0
5.8K sh
Own +54%
-
Grant·A
Director
$0
5.8K sh
Own +460%
-
Grant·A
Director
$0
5.8K sh
Own +61%
-
Exercise·M
Director
$0
4.0K sh
Own New
-
Sell·S
Director
$145.4K
4.0K sh · $36.36
Own -24%
-
Exercise·M
Director
$96.0K
4.0K sh · $24.00
Own +31%
-
Grant·A
Raul R Rodriguez KEY
CEO, President
$0
53.9K sh
Own +24%
-
Grant·A
EVP, Chief Commercial Officer
$0
19.4K sh
Own +45%
-
Grant·A
EVP, Chief Medical Officer
$0
18.9K sh
Own +118%
-
Grant·A
Dean L Schorno KEY
EVP & Chief Financial Officer
$0
20.6K sh
Own +37%
-
Grant·A
EVP, GC, CCO & Corp Sec
$0
19.5K sh
Own +60%
-
Other·F
EVP, Chief Commercial Officer
$122.8K
3.5K sh · $34.62
Own -8%
-
Other·F
Dean L Schorno KEY
EVP & Chief Financial Officer
$122.8K
3.5K sh · $34.62
Own -6%
-
Other·F
EVP, Chief Medical Officer
$130.1K
3.8K sh · $34.62
Own -19%
-
Other·F
Raul R Rodriguez KEY
CEO, President
$263.4K
7.6K sh · $34.62
Own -3%
-
Other·F
EVP, GC, CCO & Corp Sec
$122.8K
3.5K sh · $34.62
Own -10%
-
Other·F
EVP, Chief Commercial Officer
$205.9K
5.7K sh · $36.01
Own -11%
-
Other·F
Dean L Schorno KEY
EVP & Chief Financial Officer
$197.6K
5.5K sh · $36.01
Own -8%
-
Other·F
Raul R Rodriguez KEY
CEO, President
$508.1K
14.1K sh · $36.01
Own -6%
-
Other·F
EVP, GC, CCO & Corp Sec
$142.9K
4.0K sh · $36.01
Own -10%
-
Exercise·M
Raul R Rodriguez KEY
CEO, President
$0
40.0K sh
Own New
-
Other·F
Raul R Rodriguez KEY
CEO, President
$1.3M
35.4K sh · $37.00
Own -12%
-
Other·F
Raul R Rodriguez KEY
CEO, President
$1.3M
35.2K sh · $37.00
Own -13%
-
Exercise·M
Raul R Rodriguez KEY
CEO, President
$1.1M
40.0K sh · $27.40
Own +17%
-
Grant·A
Director
$0
54.9K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Dean L Schorno KEY | Exercise M | 2.2K | $0 |
| Jun 1, 2026 | Dean L Schorno KEY | Exercise M | 1.2K | $0 |
| Jun 1, 2026 | Dean L Schorno KEY | Other F | 928 | $27.7K |
| Jun 1, 2026 | Dean L Schorno KEY | Exercise M | 2.2K | $27.7K |
| Jun 1, 2026 | Dean L Schorno KEY | Exercise M | 1.2K | $22.4K |
| Jun 1, 2026 | David A Santos | Other F | 874 | $26.1K |
| Jun 1, 2026 | Lisa Rojkjaer | Other F | 850 | $25.4K |
| Jun 1, 2026 | Raul R Rodriguez KEY | Other F | 2.4K | $72.4K |
| Jun 1, 2026 | Raymond J. Furey | Other F | 877 | $26.2K |
| May 26, 2026 | Kamil Ali-Jackson 10b5-1 | Sell S | 2.5K | $72.9K |
| May 15, 2026 | Jane Wasman | Grant A | 5.8K | $0 |
| May 15, 2026 | Walter H Moos | Grant A | 5.8K | $0 |
| May 15, 2026 | Anthony Gregg Lapointe | Grant A | 5.8K | $0 |
| May 15, 2026 | Alison L. Hannah | Grant A | 5.8K | $0 |
| May 15, 2026 | Mark W Frohlich | Grant A | 5.8K | $0 |
| May 15, 2026 | Kamil Ali-Jackson | Grant A | 5.8K | $0 |
| Feb 20, 2026 | Walter H Moos | Exercise M | 4.0K | $0 |
| Feb 20, 2026 | Walter H Moos | Sell S | 4.0K | $145.4K |
| Feb 20, 2026 | Walter H Moos | Exercise M | 4.0K | $96.0K |
| Feb 17, 2026 | Raul R Rodriguez KEY | Grant A | 53.9K | $0 |
| Feb 17, 2026 | David A Santos | Grant A | 19.4K | $0 |
| Feb 17, 2026 | Lisa Rojkjaer | Grant A | 18.9K | $0 |
| Feb 17, 2026 | Dean L Schorno KEY | Grant A | 20.6K | $0 |
| Feb 17, 2026 | Raymond J. Furey | Grant A | 19.5K | $0 |
| Feb 10, 2026 | David A Santos | Other F | 3.5K | $122.8K |
| Feb 10, 2026 | Dean L Schorno KEY | Other F | 3.5K | $122.8K |
| Feb 10, 2026 | Lisa Rojkjaer | Other F | 3.8K | $130.1K |
| Feb 10, 2026 | Raul R Rodriguez KEY | Other F | 7.6K | $263.4K |
| Feb 10, 2026 | Raymond J. Furey | Other F | 3.5K | $122.8K |
| Feb 2, 2026 | David A Santos | Other F | 5.7K | $205.9K |
| Feb 2, 2026 | Dean L Schorno KEY | Other F | 5.5K | $197.6K |
| Feb 2, 2026 | Raul R Rodriguez KEY | Other F | 14.1K | $508.1K |
| Feb 2, 2026 | Raymond J. Furey | Other F | 4.0K | $142.9K |
| Jan 26, 2026 | Raul R Rodriguez KEY | Exercise M | 40.0K | $0 |
| Jan 26, 2026 | Raul R Rodriguez KEY | Other F | 35.4K | $1.3M |
| Jan 26, 2026 | Raul R Rodriguez KEY | Other F | 35.2K | $1.3M |
| Jan 26, 2026 | Raul R Rodriguez KEY | Exercise M | 40.0K | $1.1M |
| Jan 12, 2026 | Kamil Ali-Jackson | Grant A | 54.9K | $0 |
About RIGL insider trading
This page tracks insider transactions for RIGEL PHARMACEUTICALS INC (RIGL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.